Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of TAS-120 in Patients With Advanced Solid Tumors
jRCT2080222501Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- May 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of futibatinib in Nonhematologic neoplasms and solid tumor, sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of TAS-120, Pharmacokinetics of TAS-120 and 2 more. Started May 2014; status: completed.
02
Drugs
futibatinib
03
Conditions
Nonhematologic neoplasmssolid tumor
Beyond the preview
Go deeper on jRCT2080222501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222501.